Alnylam Pharma, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Lebowitz from Citi maintained a Buy rating on the stock and has a $583.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Lebowitz has given his Buy rating due to a combination of factors related to Alnylam Pharma’s promising developments with their drug zilebesiran. The recent Phase 2 KARDIA-3 trial results presented at the ESC 2025 conference showed that zilebesiran significantly reduced systolic blood pressure in patients with uncontrolled hypertension, particularly those with higher baseline blood pressure levels. This positive outcome, despite not meeting pre-specified statistical significance thresholds, indicates potential efficacy, especially in patients already on multiple blood pressure medications.
Alnylam’s strategic partnership with Roche to advance zilebesiran into a Phase 3 cardiovascular outcomes trial further supports the Buy rating. The upcoming ZENITH trial, with a target enrollment of 11,000 patients, is expected to commence soon. If successful, it could lead to FDA approval, resulting in substantial regulatory and sales milestones for Alnylam, along with a 50% share of US revenues. These prospects contribute to an expected share price return of 30.6%, reinforcing the Buy recommendation.
Lebowitz covers the Healthcare sector, focusing on stocks such as Incyte, BridgeBio Pharma, and Schrodinger. According to TipRanks, Lebowitz has an average return of 6.4% and a 57.50% success rate on recommended stocks.